c-erbB-2 oncogene as a prognostic marker in breast cancer
1991

c-erbB-2 Oncogene as a Prognostic Marker in Breast Cancer

Editorial Evidence: moderate

Author Information

Author(s): T.J. Perren

Primary Institution: Institute for Cancer Studies, St James's University Hospital

Hypothesis

Can c-erbB-2 expression serve as a reliable prognostic marker in breast cancer?

Conclusion

c-erbB-2 expression may be a useful addition to prognostic assessments in breast cancer, but larger studies are needed to confirm its significance.

Supporting Evidence

  • c-erbB-2 expression is more frequent in advanced stage and poorly differentiated tumors.
  • Previous studies have shown inconsistent results regarding the prognostic significance of c-erbB-2.
  • Larger studies are required to confirm the prognostic value of c-erbB-2 expression.

Takeaway

Scientists are studying a gene called c-erbB-2 to see if it can help predict how breast cancer will behave. It might help doctors decide how to treat patients better.

Methodology

The editorial reviews various studies on c-erbB-2 expression and its association with breast cancer prognosis.

Potential Biases

The studies may be biased due to their retrospective nature and the variability in patient characteristics.

Limitations

All studies reviewed are retrospective, limiting the availability of material and information regarding other prognostic factors.

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication